How a product moves from idea to patient
The staged lifecycle — development, non-clinical, clinical, approval, manufacturing, distribution, post-market — and why the hand-offs between stages carry the most risk.
What a module is not
A module is a reading step, not training and not a qualification. Completing it evidences that you read it — SPEQ says exactly that on the credential — and the knowledge checks are a self-check, not an assessment.
A product travels a staged journey from development to the patient, and different good practices govern each step.
Lifecycle stages map to GLP, GCP, GMP, and GDP; change control and technology transfer protect the hand-offs between them.
The seams between stages are where quality and knowledge most often leak — and where inspection findings concentrate.
A lifecycle, not a moment
A medicine or device does not simply get invented and sold. It travels a long, staged lifecycle, and different rules — different "good practices" — govern each stage. Seeing the whole journey once makes the rest of regulated work far easier to place, because almost every role, system, and requirement belongs to one of these stages.
The journey runs, roughly: discovery and development, non-clinical research, clinical research in humans, regulatory review and approval, commercial manufacturing at scale, distribution to the point of care, and post-market surveillance once the product is in real-world use. Each hand-off between stages is a place where quality and information must transfer intact.
The stages, in plain terms
Discovery and development is where a candidate is designed and characterised. Non-clinical (laboratory and animal) research studies its safety before any human is exposed — this is the domain of Good Laboratory Practice.
Clinical research tests the candidate in people under Good Clinical Practice, in carefully controlled trials that protect participants and generate credible evidence of safety and efficacy. Only after a regulator reviews that evidence and approves the product can it be sold.
Commercial manufacturing then makes the approved product at scale under Good Manufacturing Practice, held in a validated state of control so that every batch matches the one the regulator approved. Distribution moves it through the supply chain under Good Distribution Practice, preserving its quality — cold chain, security, traceability — until it reaches a patient. Finally, post-market surveillance and pharmacovigilance watch for problems that only appear once millions of people use it.
Why the hand-offs matter most
The riskiest points in the lifecycle are the seams between stages. Knowledge learned in development must reach the people who manufacture. A change made on the commercial line must be assessed against what the trial actually studied. A safety signal seen in the field must flow back to the people who control the process.
This is why regulated organisations invest so heavily in documentation, change control, and technology transfer: they are the mechanisms that carry quality and knowledge across the hand-offs without loss. When you later learn a specific requirement, ask which stage it protects and which hand-off it secures — that context is usually the key to why it exists.
- 1A product travels a staged lifecycle: development, non-clinical, clinical, approval, manufacturing, distribution, and post-market.
- 2Each stage is governed by a matching "good practice" — GLP, GCP, GMP, GDP, and pharmacovigilance.
- 3A product may only be sold after a regulator reviews the evidence and approves it.
- 4The most fragile points are the hand-offs between stages, where knowledge and quality must transfer intact.
- 5Documentation, change control, and technology transfer exist to protect those hand-offs.
Which stage must a product pass before it can be sold?
- Distribution
- Regulatory review and approval ✓
- Post-market surveillance
Which good practice governs how clinical trials are run?
- Good Manufacturing Practice
- Good Clinical Practice ✓
- Good Distribution Practice
Where does the most lifecycle risk concentrate?
- In the middle of a single stable stage
- At the hand-offs between stages ✓
- Only at the very end
A manufacturing team wants to switch to a faster mixing step that was never used during the clinical trials.
Why can they not simply make the change because it is more efficient?
The approved product is the one the regulator reviewed, made the way it was studied. A process change must be assessed through change control against what the trial and the approved filing established — because a "small" change can alter the product in ways that matter to the patient. Efficiency never overrides the hand-off between what was approved and what is made.